3SBio Inc. (HKG:1530)
31.70
+0.64 (2.06%)
Sep 3, 2025, 11:45 AM HKT
3SBio Revenue
3SBio had revenue of 4.36B CNY in the half year ending June 30, 2025, with 15.11% growth. This brings the company's revenue in the last twelve months to 9.07B, up 7.75% year-over-year. In the year 2024, 3SBio had annual revenue of 9.11B with 16.53% growth.
Revenue (ttm)
9.07B CNY
Revenue Growth
+7.75%
P/S Ratio
7.47
Revenue / Employee
1.63M CNY
Employees
5,577
Market Cap
74.29B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.11B | 1.29B | 16.53% |
Dec 31, 2023 | 7.82B | 950.20M | 13.84% |
Dec 31, 2022 | 6.87B | 483.73M | 7.58% |
Dec 31, 2021 | 6.38B | 794.37M | 14.22% |
Dec 31, 2020 | 5.59B | 269.55M | 5.07% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeOne Medicines | 35.81B |
Hansoh Pharmaceutical Group Company | 14.45B |
JD Health International | 71.34B |
Innovent Biologics | 12.52B |
Sino Biopharmaceutical | 33.49B |
Akeso | 2.75B |
WuXi Biologics | 21.98B |
CSPC Pharmaceutical Group | 28.49B |
3SBio News
- 5 weeks ago - Pfizer, Chinese biotech firm 3SBio complete licensing deal for cancer drug - South China Morning Post
- 3 months ago - Pfizer's Mega Deal Highlights China's Rising Role In Global Pharma - Benzinga
- 3 months ago - Pfizer Thinks Bigger With 3SBio Deal - Seeking Alpha
- 3 months ago - Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China - Investopedia
- 3 months ago - Pfizer strikes deal with China's 3SBio to license cancer drug - CNBC
- 3 months ago - Pfizer Secures Global Rights To China's 3SBio's Cancer Drug In $6 Billion Deal - Benzinga